Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,14%
1 079,04
-12,47
-1,14%
—1 091,511 090,401 090,401 075,55——
SIXC
Communications
SIXC
Communications
SIXC
-0,26%
608,55
-1,56
-0,26%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,76%
1 247,37
+9,39
+0,76%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,92%
1 728,68
-16,03
-0,92%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,23%
638,71
-1,47
-0,23%
—640,18639,92643,19636,28——
SIXR
Staples
SIXR
Staples
SIXR
-0,53%
845,08
-4,50
-0,53%
—849,58845,27851,68841,28——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,33%
216,77
-0,71
-0,33%
—217,48217,48218,16216,37——
SIXT
Technology
SIXT
Technology
SIXT
-0,11%
3 257,15
-3,54
-0,11%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,35%
939,16
-3,29
-0,35%
—942,45939,39948,80934,04——
SIXV
Health care
SIXV
Health care
SIXV
-0,32%
1 462,16
-4,64
-0,32%
—1 466,801 464,701 467,191 458,68——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,77%
2 378,99
-18,51
-0,77%
—2 397,502 395,032 412,012 370,64——
NVS:BCBA
«Նովարտիս»
10 800,00 ARS
0,00%
(0,00) 1D
19 ապր, 16:40:36 GMT-3  ·   ARS
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Mkt. cap
292,18 մլրդ
Volume
0,00
Shares outstanding
2,03 մլրդ
No. of employees
75 հզր
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About «Նովարտիս»
CEOVasant Narasimhan
Employees75,3 հզր
Founded29 փտվ, 1996 թ.
HeadquartersԲասել, Basel City, Շվեյցարիա
Sector-
Websitenovartis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
14,84 մլրդ
14,36 մլրդ
13,86 մլրդ
13,52 մլրդ
Cost of goods sold
3,32 մլրդ
3,54 մլրդ
3,54 մլրդ
3,44 մլրդ
Cost of revenue
3,32 մլրդ
3,54 մլրդ
3,54 մլրդ
3,44 մլրդ
Research and development expenses
2,62 մլրդ
2,86 մլրդ
2,84 մլրդ
2,78 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,44 մլրդ
3,30 մլրդ
3,44 մլրդ
3,14 մլրդ
Operating expense
6,05 մլրդ
6,24 մլրդ
6,46 մլրդ
5,96 մլրդ
Total operating expenses
9,37 մլրդ
9,77 մլրդ
10,00 մլրդ
9,40 մլրդ
Operating income
5,46 մլրդ
4,58 մլրդ
3,86 մլրդ
4,12 մլրդ
Other non operating income
-13,00 մլն
-7,00 մլն
-130,00 մլն
4,00 մլն
EBT including unusual items
4,53 մլրդ
4,20 մլրդ
3,22 մլրդ
3,84 մլրդ
EBT excluding unusual items
5,16 մլրդ
4,29 մլրդ
3,49 մլրդ
3,78 մլրդ
Income tax expense
507,00 մլն
266,00 մլն
814,00 մլն
683,00 մլն
Effective tax rate
11,19%
6,34%
25,30%
17,79%
Other operating expenses
-4,00 մլն
70,00 մլն
190,00 մլն
42,00 մլն
Net income
4,04 մլրդ
3,93 մլրդ
2,41 մլրդ
3,16 մլրդ
Net profit margin
27,24%
27,36%
17,38%
23,34%
Earnings per share
2,42
2,25
2,03
1,99
Interest and investment income
-
-
373,00 մլն
-
Interest expense
-289,00 մլն
-281,00 մլն
-304,00 մլն
-343,00 մլն
Net interest expenses
-289,00 մլն
-281,00 մլն
69,00 մլն
-343,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
6,56 մլրդ
5,78 մլրդ
4,96 մլրդ
5,24 մլրդ
Gain or loss from assets sale
-67,00 մլն
81,00 մլն
80,00 մլն
-159,00 մլն
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer